Reply to: "correspondence about "Efficacy and safety of basiliximab".

Hashim, Mohamed; Alsebaey, Ayman; Ragab, Amr; Soliman, Hossam Eldeen; Waked, Imam

Hashim, Mohamed; Alsebaey, Ayman; Ragab, Amr; Soliman, Hossam Eldeen; Waked, Imam.

Afiliação

Hashim M; Department of Hepatology, National Liver Institute, Menoufiya University, Shebin Elkom, Egypt. Electronic address: msaadhh@hotmail.com.
Alsebaey A; Department of Hepatology, National Liver Institute, Menoufiya University, Shebin Elkom, Egypt.
Ragab A; Department of Hepatology, National Liver Institute, Menoufiya University, Shebin Elkom, Egypt.
Soliman HE; Department of Hepatobiliary and Pancreatic Surgery, National Liver Institute, Menoufiya University, Shebin Elkom, Egypt.
Waked I; Department of Hepatology, National Liver Institute, Menoufiya University, Shebin Elkom, Egypt.

Ann Hepatol ; 27(2): 100679, 2022.

Article em En | MEDLINE | ID: mdl-35101617

Assuntos

Rejeição de Enxerto; Imunossupressores; Basiliximab; Humanos

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Rejeição de Enxerto / Imunossupressores Limite: Humans Idioma: En Revista: Ann Hepatol Assunto da revista: GASTROENTEROLOGIA Ano de publicação: 2022 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google